SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-008577
Filing Date
2020-07-29
Accepted
2020-07-29 10:43:45
Documents
61
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q anvs-20200630x10q.htm 10-Q 728708
2 EX-31.1 anvs-20200630ex311d56ddd.htm EX-31.1 12607
3 EX-31.2 anvs-20200630ex3123653d5.htm EX-31.2 12641
4 EX-32.1 anvs-20200630ex3214ee20f.htm EX-32.1 5717
5 EX-32.2 anvs-20200630ex322021a58.htm EX-32.2 5703
  Complete submission text file 0001558370-20-008577.txt   3606928

Data Files

Seq Description Document Type Size
6 EX-101.INS anvs-20200630.xml EX-101.INS 561120
7 EX-101.SCH anvs-20200630.xsd EX-101.SCH 46808
8 EX-101.CAL anvs-20200630_cal.xml EX-101.CAL 29712
9 EX-101.DEF anvs-20200630_def.xml EX-101.DEF 156848
10 EX-101.LAB anvs-20200630_lab.xml EX-101.LAB 367154
11 EX-101.PRE anvs-20200630_pre.xml EX-101.PRE 271424
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

IRS No.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39202 | Film No.: 201056211
SIC: 2834 Pharmaceutical Preparations